ClinicalTrials.gg
CompletedNCT02471144Updated Oct 11, 2023Results posted

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

A Phase 3 interventional study of Experimental : Secukinumab low dose and Experimental: Secukinumab high dose in Chronic Severe Plaque-type Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 46 sites in 19 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-10-11.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 68 studies in Psoriasis by Novartis — 3 open to participants now, 4 under way, none of them phase 3. Psoriasis · Novartis.

Enrollment
28th of 53
162 · median 177
Started
2015
with 7 others
Phase 3
30 of 68
none open now
Registered
36th of 68
by date

Among the 68 studies in Psoriasis by Novartis, this one is the 28th largest by enrollment of the 53 interventional ones that give a count, is one of 8 that started in 2015, is one of 30 in phase 3, and was the 36th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

3 of the 68 studies in Psoriasis by Novartis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 174 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 41 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Psoriasis by Novartis, or all of them as a file.
02

Study summary

This was a multicenter, randomized, double-blind, placebo- and active-controlled (etanercept in single blinded arm) study in pediatric subjects aged 6 years to less than 18 years with severe chronic plaque psoriasis. Approximately 160 subjects aged 6 years to \<18 years were enrolled, of which at least 30 were 6 years to \<12 years old. Subjects were enrolled at approximately 70 study sites worldwide.

Read the detailed description

The purpose of this study was to demonstrate superior efficacy of secukinumab versus placebo at Week 12, based on both PASI 75 and IGA mod 2011 0 or 1 response rates in children and adolescents aged 6 to less than 18 years with severe chronic plaque psoriasis who had inadequate control of symptoms with topical treatment, or failed to respond to or tolerate previous systemic treatment and/or UV therapy

The study assessed the long term safety and tolerability of secukinumab in this pediatric age group and described the efficacy and safety of secukinumab compared to etanercept. This study provided efficacy and safety data to support the extension of label of secukinumab to include children and adolescents (6 years to \<18 years) with severe chronic plaque psoriasis

Two age subgroups were studied in a staggered approach within this clinical study: 12 to less than 18 years of age, and 6 to less than 12 years of age . Enrolment of children aged 6 to less than 12 years began after a favorable recommendation by an independent external Data Monitoring Committee (DMC) who reviewed data of approximately 80 adolescents. Adolescents continued to be recruited while the data from the first 80 subjects was being collected and analyzed

Subjects were randomized using a 1:1:1:1 ratio into one of the treatment arms: secukinumab low dose, secukinumab high dose, etanercept or placebo. Subjects randomized to secukinumab treatment arms (high dose and low dose) received dose based on the weight category (\<25 kg, 25 to \<50kg, ≥50 kg).

The study consisted of 5 periods: screening (up to 4 weeks), induction (of 12 weeks), maintenance (of 40 weeks), extension treatment epoch (open-label of 184 weeks) and post- treatment follow-up epoch (of 16 weeks).

The screening period of up to 4 weeks was used to assess eligibility of the patients and to taper patients off prohibited medications.

The Induction period is defined as randomization through Week 12. In this period, the study was both active and placebo-controlled and at its completion, the primary endpoint was assessed (Week 12).

The Maintenance period is defined as Week 12 (from dosing) through Week 52. During this period, the study was active-controlled, and the objectives focused on the maintenance of the response observed at Week 12.

Patients who received secukinumab or etanercept during induction continued in maintenance with the same treatment. Patients who were on placebo during induction and at Week 12 were PASI 75 non-responders were switched to either secukinumab low dose or secukinumab high dose treatment group in the Maintenance period according to their baseline randomization.

At the end of the Maintenance period, all patients on secukinumab entered the Extension treatment period and continued to receive the same dose of secukinumab. The Extension treatment period was defined as Week 52 (from dosing) until Week 236. In this period, all patients were treated with secukinumab, and the purpose was the collection of long-term safety and efficacy data.

Patients who participated in the Maintenance period but prematurely discontinued the study were not able to enter the Extension treatment period. Patients receiving etanercept were not eligible to enter the Extension treatment period. Instead, at Week 52, they completed an EOM visit and then entered the post-treatment Follow-up period.

03

Conditions studied

  • Chronic Severe Plaque-type Psoriasis

Browse trials for

Keywords

  • pediatric
  • chronic severe plaque psoriasis
  • secukinumab
  • etanercept
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be 6 to less than 18 years of age at the time of randomization
  • Plaque-type psoriasis history for at least 3 months.

Severe plaque-type psoriasis meeting all of the following three criteria:

  • PASI score of 20 or greater,
  • Investigator's Global Assessment (IGA) score of 4
  • Total body surface area (BSA) affected of 10% or greater.
  • Patient being regarded by the investigator to be a candidate for systemic therapy because of:

    1. inadequate control of symptoms with topical treatment, or
    2. failure to respond to or tolerate previous systemic treatment and/or UV therapy

Exclusion criteria

Exclusion criteria

  • Current forms of psoriasis other than chronic plaque-type psoriasis (for example, pustular, erythrodermic, guttate) at randomization.
  • Current drug-induced psoriasis.
  • Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor.
  • Underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal) which in the opinion of the investigator significantly immunocompromises the subject and/or places the subject at unacceptable risk for receiving an immunomodulatory therapy
  • History of an ongoing, chronic or recurrent infectious disease, or evidence of untreated tuberculosis.
  • History of lymphoproliferative disease or history of of any organ system within the past 5 years.
  • Pregnant or nursing (lactating) women.
  • Other protocol-defined inclusion/exclusion criteria may apply.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
162 participants (actual)

Study arms

  • Experimental
    Secukinumab low dose

    Secukinumab

    Biological: Experimental : Secukinumab low dose

  • Experimental
    Secukinumab high dose

    Secukinumab

    Biological: Experimental: Secukinumab high dose

  • Placebo comparator
    Placebo

    Placebo

    Biological: Placebo Comparator: Secukinumab Placebo

  • Active comparator
    Etanercept Comparator

    Etanercept

    Biological: Active Comparator: Etanercept

Interventions

  • BiologicalExperimental : Secukinumab low dose

    Depending on weight group subject will receive per dose a) 75 mg if weighing less than 50 kg b) 150 mg if weighing 50 kg or more. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.

    Also known as: AIN457 low dose

  • BiologicalExperimental: Secukinumab high dose

    Depending on weight group subject will receive per dose a) 75 mg if weighing less than 25 kg b) 150 mg if weighing between 25 and less than 50 kg c) 300 mg if weighing more than 50 kg. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.

    Also known as: AIN457 high dose

  • BiologicalPlacebo Comparator: Secukinumab Placebo

    Placebo secukinumab (one or two subcutaneous injections per dose, depending on weight group) at Randomization and Weeks 1, 2, 3 4 and 8. At Week 12, subjects in the placebo group based on their PASI 75 response status at Week 12 will proceed as follows: • PASI 75 responders will discontinue study treatment at Week 12 and enter the treatment-free follow-up period • PASI 75 non-responders will receive high dose or low dose secukinumab, according to the pre-assignment at the Randomization visit. They will receive their treatment based on the weight category(\<25 kg, 25- \<50kg, ≥50 kg), on Weeks 12, 13, 14, 15, and then every four weeks starting at Week 16 until Week 48 during the maintenance period; thereafter at week 52 and every 4 weeks during the extension treatment period until Week 232.

    Also known as: AIN457 placebo

  • Etanercept 0.8 mg/kg of subject weight and up to a maximum of 50 mg per dose. Subcutaneous etanercept 0.8 mg/kg (one or two injections per dose) once per week, for 51 weeks administered at home (self-injected or by caregiver) or at the study site. At Wk 52 subjects in the etanercept group will move into the treatment-free follow up period and terminate the study.

    Also known as: Etanercept

06

What researchers measure

Primary outcomes

  1. Number and Percentage of Participants Achieving a 75% Improvement From Baseline in PASI Score at Week 12

    Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 75 represents the percentage (or number) of patients who have achieved a 75% or more reduction in their PASI score from baseline.

    Time frame: 12 weeks

  2. Number and Percentage of Participants Who Showed Investigator's Global Assessment (IGA) Mod 2011 Response of 0 or 1 at Week 12

    IGA: The IGA mod 2011 scale has following different scores for the state of disease: 0: Clear, No signs of psoriasis. 1: Almost clear 2: Mild 3: Moderate 4 : Severe

    Time frame: 12 Weeks

Secondary outcomes

  1. Number and Percentage of Participants Achieving a 90% Improvement From Baseline in PASI Score at Week 12

    Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 90 represents the percentage (or number) of patients who have achieved a 90% or more reduction in their PASI score from baseline.

    Time frame: 12 weeks

  2. Number and Percentage of Participants Achieving a 50%, 100% Improvement From Baseline in PASI Score at Week 12

    Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 50 represents the percentage (or number) of patients who have achieved a 50% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.

    Time frame: 12 weeks

  3. Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 up to Week 12 (Induction)

    Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema, Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). PASI will be assessed/calculated as per standard procedure. IGA: The IGA mod 2011 scale has following different scores for the state of disease: 0: Clear, No signs of psoriasis. 1: Almost clear 2: Mild 3: Moderate 4 : Severe

    Time frame: Weeks 4, 8

  4. Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance)

    Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema, Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). PASI will be assessed/calculated as per standard procedure. IGA: The IGA mod 2011 scale has following different scores for the state of disease: 0: Clear, No signs of psoriasis. 1: Almost clear 2: Mild 3: Moderate 4 : Severe

    Time frame: Weeks 16, 20, 24, 36, 48 and 52

  5. Change From Baseline in Psoriasis Area & Severity Index (PASI) Score at Week 12

    Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 75 represents the percentage (or number)of patients who have achieved a 75% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.

    Time frame: Week 12

  6. Change From Baseline in Psoriasis Area & Severity Index (PASI) Scores at Week 52

    Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 75 represents the percentage (or number)of patients who have achieved a 75% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.

    Time frame: Week 52

  7. Percentage of Participants in IGA Mod 2011 Score Categories at Week 12

    IGA: The IGA mod 2011 scale has following different scores for the state of disease: 0: Clear, No signs of psoriasis. 1: Almost clear 2: Mild 3: Moderate 4 : Severe

    Time frame: Week 12

  8. Percentage of Participants in IGA Mod 2011 Score Categories at Week 52

    IGA: The IGA mod 2011 scale has following different scores for the state of disease: 0: Clear, No signs of psoriasis. 1: Almost clear 2: Mild 3: Moderate 4 : Severe

    Time frame: Week 52

  9. Percentage Change From Baseline in Children's Dermatology Life Quality Index (cDLQI) Score Up to Week 12 (Induction)

    The CDLQI measures functional disability of subjects with dermatological disorders who are less than 18 years of age and it has been utilized as a relevant clinical measure in atopic dermatitis, as well as other dermatitis clinical trials. The CDLQI is a simple, validated, self-administered 10-item questionnaire. The instrument contains six functional scales (i.e., symptoms and feeling, leisure, school or holidays, personal relationships, sleep and treatment). The questions are based on the preceding week to permit accurate recall. For the CDLQI, each question will be answered on a 4-point Likert scale scored from 0 to 3. Seven scores will be derived from the CDLQI: the total score of each of the six dimensions as well as the total score over all items. The higher the score, the more quality of life is impaired.

    Time frame: Weeks 4, 8, 12

  10. Percentage Change From Baseline in Children's Dermatology Life Quality Index (cDLQI) Score Up to Week 52 (Maintenance)

    The CDLQI measures functional disability of subjects with dermatological disorders who are less than 18 years of age and it has been utilized as a relevant clinical measure in atopic dermatitis, as well as other dermatitis clinical trials. The CDLQI is a simple, validated, self-administered 10-item questionnaire. The instrument contains six functional scales (i.e., symptoms and feeling, leisure, school or holidays, personal relationships, sleep and treatment). The questions are based on the preceding week to permit accurate recall. For the CDLQI, each question will be answered on a 4-point Likert scale scored from 0 to 3. Seven scores will be derived from the CDLQI: the total score of each of the six dimensions as well as the total score over all items. The higher the score, the more quality of life is impaired.

    Time frame: Weeks 24, 36, 52

  11. Number and Percentage of Participants Achieving a Children's DLQI Score of 0 or 1 Over Time up to Week 12 (Induction)

    The CDLQI measures functional disability of subjects with dermatological disorders who are less than 18 years of age and it has been utilized as a relevant clinical measure in atopic dermatitis, as well as other dermatitis clinical trials. The CDLQI is a simple, validated, self-administered 10-item questionnaire. The instrument contains six functional scales (i.e., symptoms and feeling, leisure, school or holidays, personal relationships, sleep and treatment). The questions are based on the preceding week to permit accurate recall. For the CDLQI, each question will be answered on a 4-point Likert scale scored from 0 to 3. Seven scores will be derived from the CDLQI: the total score of each of the six dimensions as well as the total score over all items. The higher the score, the more quality of life is impaired.

    Time frame: Weeks 4, 8, 12

  12. Number and Percentage of Participants Achieving a Children's DLQI Score of 0 or 1 Over Time up to Week 52 (Maintenance)

    The CDLQI measures functional disability of subjects with dermatological disorders who are less than 18 years of age and it has been utilized as a relevant clinical measure in atopic dermatitis, as well as other dermatitis clinical trials. The CDLQI is a simple, validated, self-administered 10-item questionnaire. The instrument contains six functional scales (i.e., symptoms and feeling, leisure, school or holidays, personal relationships, sleep and treatment). The questions are based on the preceding week to permit accurate recall. For the CDLQI, each question will be answered on a 4-point Likert scale scored from 0 to 3. Seven scores will be derived from the CDLQI: the total score of each of the six dimensions as well as the total score over all items. The higher the score, the more quality of life is impaired.

    Time frame: Weeks 24, 36, 52

  13. Number and Percentage of Participants With Clinically Important Reduction in Disability as Evaluated by CHAQ Questionnaire Over Time at Week 12

    The CHAQ questionnaire is only done for children who in addition to psoriasis are also suffering from psoriatic arthritis. The questionnaire is completed by parent or legal guardian. It consists of multiple choice items concerning difficulty in performing eight common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and other "activities". The person completing the questionnaire chooses from four response categories, ranging from 'without any difficulty' to 'unable to do'. Additionally two visual analog scales (overall well-being and pain of patient) must be performed.

    Time frame: Week 12

  14. Number and Percentage of Participants With Clinically Important Reduction in Disability as Evaluated by CHAQ Questionnaire Over Time at Week 52

    The CHAQ questionnaire is only done for children who in addition to psoriasis are also suffering from psoriatic arthritis. The questionnaire is completed by parent or legal guardian. It consists of multiple choice items concerning difficulty in performing eight common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and other "activities". The person completing the questionnaire chooses from four response categories, ranging from 'without any difficulty' to 'unable to do'. Additionally two visual analog scales (overall well-being and pain of patient) must be performed.

    Time frame: Week 52

07

Results

Posted Aug 16, 2021

Participant flow

This was a multicenter, randomized, double-blind, placebo- and active-controlled (etanercept in single blinded arm) study in pediatric patients aged 6 years to less than 18 years with severe chronic plaque psoriasis. A total of 187 patients were screened, of which 162 were randomized.

Induction Period (Up to Week 12)
Participant flow — Induction Period (Up to Week 12)
MilestoneAIN457 Low Dose (Induction Period)AIN457 High Dose (Induction Period)Placebo (Induction Period)Etanercept Comparator (Induction Period)AIN457 Low Dose (Maintenance Period)AIN457 High Dose (Maintenance Period)Placebo-AIN457 Low Dose (Maintenance Period)Placebo-AIN457 High Dose (Maintenance PeriodEtanercept Comparator (Maintenance Period)Any AIN457 Low Dose (Extension Period)Any AIN457 High Dose (Extension Period)
Started404041410000000
Completed393839400000000
Not completed12210000000
Withdrew: Adverse event01100000000
Withdrew: Lack of efficacy00010000000
Withdrew: Protocol deviation00100000000
Withdrew: Subject/guardian decision11000000000
Maintenance Period (Week 12 to Week 52)
Participant flow — Maintenance Period (Week 12 to Week 52)
MilestoneAIN457 Low Dose (Induction Period)AIN457 High Dose (Induction Period)Placebo (Induction Period)Etanercept Comparator (Induction Period)AIN457 Low Dose (Maintenance Period)AIN457 High Dose (Maintenance Period)Placebo-AIN457 Low Dose (Maintenance Period)Placebo-AIN457 High Dose (Maintenance PeriodEtanercept Comparator (Maintenance Period)Any AIN457 Low Dose (Extension Period)Any AIN457 High Dose (Extension Period)
Started0000393816184000
Completed0000383715163400
Not completed00001112600
Withdrew: Adverse event00001010100
Withdrew: Lack of efficacy00000100300
Withdrew: Pregnancy00000000100
Withdrew: Protocol deviation00000002100
Extension Period (Week 52 to Week 236)
Participant flow — Extension Period (Week 52 to Week 236)
MilestoneAIN457 Low Dose (Induction Period)AIN457 High Dose (Induction Period)Placebo (Induction Period)Etanercept Comparator (Induction Period)AIN457 Low Dose (Maintenance Period)AIN457 High Dose (Maintenance Period)Placebo-AIN457 Low Dose (Maintenance Period)Placebo-AIN457 High Dose (Maintenance PeriodEtanercept Comparator (Maintenance Period)Any AIN457 Low Dose (Extension Period)Any AIN457 High Dose (Extension Period)
Started0000000005353
Completed0000000003943
Not completed0000000001410
Withdrew: Lack of efficacy00000000063
Withdrew: Pregnancy00000000020
Withdrew: Lost to follow-up00000000002
Withdrew: Adverse event00000000022
Withdrew: Technical problems00000000010
Withdrew: Subject/guardian decision00000000033

Outcome measures

PrimaryNumber and Percentage of Participants Achieving a 75% Improvement From Baseline in PASI Score at Week 12

Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 75 represents the percentage (or number) of patients who have achieved a 75% or more reduction in their PASI score from baseline.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Number and Percentage of Participants Achieving a 75% Improvement From Baseline in PASI Score at Week 12
ParticipantsAIN457 Low DoseAIN457 High DosePlaceboEtanercept
Number and Percentage of Participants Achieving a 75% Improvement From Baseline in PASI Score at Week 123231626
Statistical analysis
  • AIN457 Low Dose · Regression, Logistic · p = <.0001 · Odds ratio (or): 25.78 · 95% CI 7.08 to 114.66
  • AIN457 High Dose · Regression, Logistic · p = <.0001 · Odds ratio (or): 22.65 · 95% CI 6.31 to 98.93
PrimaryNumber and Percentage of Participants Who Showed Investigator's Global Assessment (IGA) Mod 2011 Response of 0 or 1 at Week 12

IGA: The IGA mod 2011 scale has following different scores for the state of disease: 0: Clear, No signs of psoriasis. 1: Almost clear 2: Mild 3: Moderate 4 : Severe

Time frame:
12 Weeks
Reported as:
Count of participants · Participants
Number and Percentage of Participants Who Showed Investigator's Global Assessment (IGA) Mod 2011 Response of 0 or 1 at Week 12
ParticipantsAIN457 Low DoseAIN457 High DosePlaceboEtanercept
Number and Percentage of Participants Who Showed Investigator's Global Assessment (IGA) Mod 2011 Response of 0 or 1 at Week 122824214
Statistical analysis
  • AIN457 Low Dose · Regression, Logistic · p = <.0001 · Odds ratio (or): 51.77 · 95% CI 10.02 to 538.64
  • AIN457 High Dose · Regression, Logistic · p = <.0001 · Odds ratio (or): 32.52 · 95% CI 6.48 to 329.52
SecondaryNumber and Percentage of Participants Achieving a 90% Improvement From Baseline in PASI Score at Week 12

Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 90 represents the percentage (or number) of patients who have achieved a 90% or more reduction in their PASI score from baseline.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Number and Percentage of Participants Achieving a 90% Improvement From Baseline in PASI Score at Week 12
ParticipantsAIN457 Low DoseAIN457 High DosePlaceboEtanercept
Number and Percentage of Participants Achieving a 90% Improvement From Baseline in PASI Score at Week 122927112
Statistical analysis
  • AIN457 Low Dose · Regression, Logistic · p = <.0001 · Odds ratio (or): 72.5 · 95% CI 55.9 to 84.9
  • AIN457 High Dose · Regression, Logistic · p = <.0001 · Odds ratio (or): 67.5 · 95% CI 50.8 to 80.9
SecondaryNumber and Percentage of Participants Achieving a 50%, 100% Improvement From Baseline in PASI Score at Week 12

Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 50 represents the percentage (or number) of patients who have achieved a 50% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Number and Percentage of Participants Achieving a 50%, 100% Improvement From Baseline in PASI Score at Week 12
ParticipantsAIN457 Low DoseAIN457 High DosePlaceboEtanercept
PASI 503434934
PASI 100121107
SecondaryNumber and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 up to Week 12 (Induction)

Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema, Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). PASI will be assessed/calculated as per standard procedure. IGA: The IGA mod 2011 scale has following different scores for the state of disease: 0: Clear, No signs of psoriasis. 1: Almost clear 2: Mild 3: Moderate 4 : Severe

Time frame:
Weeks 4, 8
Reported as:
Count of participants · Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 up to Week 12 (Induction)
ParticipantsAIN457 Low DoseAIN457 High DosePlaceboEtanercept
Week 4- IGA 0/161301
Week 4- PASI 502628619
Week 4- PASI 75132205
Week 4- PASI 905901
Week 4- PASI 1003300
Week 8- IGA 0/1211806
Week 8- PASI 5032321130
Week 8- PASI 752726115
Week 8- PASI 90202004
Week 8-PASI 1009702
SecondaryNumber and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance)

Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema, Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). PASI will be assessed/calculated as per standard procedure. IGA: The IGA mod 2011 scale has following different scores for the state of disease: 0: Clear, No signs of psoriasis. 1: Almost clear 2: Mild 3: Moderate 4 : Severe

Time frame:
Weeks 16, 20, 24, 36, 48 and 52
Reported as:
Count of participants · Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance)
ParticipantsAIN457 Low DoseAIN457 High DosePlacebo-AIN457 Low DosePlacebo- AIN457 High DoseEtanercept
Week 16- IGA 0/132285819
Week 16- PASI 503735111630
Week 16- PASI 75363251126
Week 16- PASI 9033304716
Week 16- PASI 1001914018
Week 20- IGA 0/13328121321
Week 20- PASI 503836151732
Week 20- PASI 753835131529
Week 20- PASI 903330121219
Week 20- PASI 1002016548
Week 24- IGA 0/13530141420
Week 24- PASI 503837151631
Week 24- PASI 753735151426
Week 24- PASI 903331131219
Week 24- PASI 1002217769
Week 36- IGA 0/13229141421
Week 36- PASI 503737161631
Week 36- PASI 753535161626
Week 36-PASI 90323110718
Week 36-PASI 100172010710
Week 48- IGA 0/12828141421
Week 48-PASI 503835151531
Week 48- PASI 753535141527
Week 48- PASI 902930121423
Week 48- PASI 100161810812
Week 52- 1GA 0/12930141323
Week 52- PASI 503937151732
Week 52- PASI 753535141728
Week 52- PASI 903032131421
Week 52- PASI 100161910109
SecondaryChange From Baseline in Psoriasis Area & Severity Index (PASI) Score at Week 12

Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 75 represents the percentage (or number)of patients who have achieved a 75% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.

Time frame:
Week 12
Reported as:
Mean · Scores on a scale
Change From Baseline in Psoriasis Area & Severity Index (PASI) Score at Week 12
Scores on a scaleAIN457 Low DoseAIN457 High DosePlaceboEtanercept
Change From Baseline in Psoriasis Area & Severity Index (PASI) Score at Week 12-22.27 ± 8.518-22.67 ± 11.904-7.94 ± 9.396-20.91 ± 10.055
SecondaryChange From Baseline in Psoriasis Area & Severity Index (PASI) Scores at Week 52

Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 75 represents the percentage (or number)of patients who have achieved a 75% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.

Time frame:
Week 52
Reported as:
Mean · Scores on a scale
Change From Baseline in Psoriasis Area & Severity Index (PASI) Scores at Week 52
Scores on a scaleAIN457 Low DoseAIN457 High DosePlacebo-AIN457 Low DosePlacebo-AIN457 High DoseEtanercept
Change From Baseline in Psoriasis Area & Severity Index (PASI) Scores at Week 52-25.26 ± 7.150-25.75 ± 8.593-28.49 ± 7.984-24.69 ± 5.520-21.16 ± 11.779
SecondaryPercentage of Participants in IGA Mod 2011 Score Categories at Week 12

IGA: The IGA mod 2011 scale has following different scores for the state of disease: 0: Clear, No signs of psoriasis. 1: Almost clear 2: Mild 3: Moderate 4 : Severe

Time frame:
Week 12
Reported as:
Count of participants · Participants
Percentage of Participants in IGA Mod 2011 Score Categories at Week 12
ParticipantsAIN457 Low DoseAIN457 High DosePlaceboEtanercept
Week 12- IGA Category: Clear121107
Week 12- IGA Category: Almost Clear141327
Week 12- IGA Category: Mild Disease87418
Week 12- IGA Category: Moderate Disease34116
Week 12- IGA Category: Severe Disease24233
SecondaryPercentage of Participants in IGA Mod 2011 Score Categories at Week 52

IGA: The IGA mod 2011 scale has following different scores for the state of disease: 0: Clear, No signs of psoriasis. 1: Almost clear 2: Mild 3: Moderate 4 : Severe

Time frame:
Week 52
Reported as:
Count of participants · Participants
Percentage of Participants in IGA Mod 2011 Score Categories at Week 52
ParticipantsAIN457 Low DoseAIN457 High DosePlacebo-AIN457 Low DosePlacebo-AIN457 High DoseEtanercept
Week 52- IGA Category: Clear162010109
Week 52- IGA Category: Almost Clear13104414
Week 52- IGA Category: Mild Disease74249
Week 52- IGA Category: Moderate Disease22004
Week 52- IGA Category: Severe Disease13005
SecondaryPercentage Change From Baseline in Children's Dermatology Life Quality Index (cDLQI) Score Up to Week 12 (Induction)

The CDLQI measures functional disability of subjects with dermatological disorders who are less than 18 years of age and it has been utilized as a relevant clinical measure in atopic dermatitis, as well as other dermatitis clinical trials. The CDLQI is a simple, validated, self-administered 10-item questionnaire. The instrument contains six functional scales (i.e., symptoms and feeling, leisure, school or holidays, personal relationships, sleep and treatment). The questions are based on the preceding week to permit accurate recall. For the CDLQI, each question will be answered on a 4-point Likert scale scored from 0 to 3. Seven scores will be derived from the CDLQI: the total score of each of the six dimensions as well as the total score over all items. The higher the score, the more quality of life is impaired.

Time frame:
Weeks 4, 8, 12
Reported as:
Mean · percentage change of score
Percentage Change From Baseline in Children's Dermatology Life Quality Index (cDLQI) Score Up to Week 12 (Induction)
percentage change of scoreAIN457 Low DoseAIN457 High DosePlaceboEtanercept
Week 4-47.71 ± 45.743-50.71 ± 37.0031.67 ± 104.216-35.13 ± 56.832
Week 8-61.60 ± 54.371-66.97 ± 32.040-17.77 ± 66.451-42.73 ± 54.026
Week 12-67.43 ± 41.602-62.5 ± 50.08-18.48 ± 80.018-62.80 ± 34.419
SecondaryPercentage Change From Baseline in Children's Dermatology Life Quality Index (cDLQI) Score Up to Week 52 (Maintenance)

The CDLQI measures functional disability of subjects with dermatological disorders who are less than 18 years of age and it has been utilized as a relevant clinical measure in atopic dermatitis, as well as other dermatitis clinical trials. The CDLQI is a simple, validated, self-administered 10-item questionnaire. The instrument contains six functional scales (i.e., symptoms and feeling, leisure, school or holidays, personal relationships, sleep and treatment). The questions are based on the preceding week to permit accurate recall. For the CDLQI, each question will be answered on a 4-point Likert scale scored from 0 to 3. Seven scores will be derived from the CDLQI: the total score of each of the six dimensions as well as the total score over all items. The higher the score, the more quality of life is impaired.

Time frame:
Weeks 24, 36, 52
Reported as:
Mean · percentage change of score
Percentage Change From Baseline in Children's Dermatology Life Quality Index (cDLQI) Score Up to Week 52 (Maintenance)
percentage change of scoreAIN457 Low DoseAIN457 High DosePlacebo-AIN457 Low DosePlacebo-AIN457 High DoseEtanercept
Week 24-73.7 ± 55.02-53.9 ± 74.6340.3 ± 477.93-73.8 ± 53.09-55.0 ± 44.98
Week 36-79.0 ± 31.99-56.2 ± 107.65-89.5 ± 19.11-69.4 ± 46.46-47.7 ± 45.01
Week 52-80.9 ± 39.38-58.6 ± 77.56-89.0 ± 15.73-86.0 ± 23.19-53.4 ± 56.99
SecondaryNumber and Percentage of Participants Achieving a Children's DLQI Score of 0 or 1 Over Time up to Week 12 (Induction)

The CDLQI measures functional disability of subjects with dermatological disorders who are less than 18 years of age and it has been utilized as a relevant clinical measure in atopic dermatitis, as well as other dermatitis clinical trials. The CDLQI is a simple, validated, self-administered 10-item questionnaire. The instrument contains six functional scales (i.e., symptoms and feeling, leisure, school or holidays, personal relationships, sleep and treatment). The questions are based on the preceding week to permit accurate recall. For the CDLQI, each question will be answered on a 4-point Likert scale scored from 0 to 3. Seven scores will be derived from the CDLQI: the total score of each of the six dimensions as well as the total score over all items. The higher the score, the more quality of life is impaired.

Time frame:
Weeks 4, 8, 12
Reported as:
Count of participants · Participants
Number and Percentage of Participants Achieving a Children's DLQI Score of 0 or 1 Over Time up to Week 12 (Induction)
ParticipantsAIN457 Low DoseAIN457 High DosePlaceboEtanercept
Week 481129
Week 81519710
Week 121719615
SecondaryNumber and Percentage of Participants Achieving a Children's DLQI Score of 0 or 1 Over Time up to Week 52 (Maintenance)

The CDLQI measures functional disability of subjects with dermatological disorders who are less than 18 years of age and it has been utilized as a relevant clinical measure in atopic dermatitis, as well as other dermatitis clinical trials. The CDLQI is a simple, validated, self-administered 10-item questionnaire. The instrument contains six functional scales (i.e., symptoms and feeling, leisure, school or holidays, personal relationships, sleep and treatment). The questions are based on the preceding week to permit accurate recall. For the CDLQI, each question will be answered on a 4-point Likert scale scored from 0 to 3. Seven scores will be derived from the CDLQI: the total score of each of the six dimensions as well as the total score over all items. The higher the score, the more quality of life is impaired.

Time frame:
Weeks 24, 36, 52
Reported as:
Count of participants · Participants
Number and Percentage of Participants Achieving a Children's DLQI Score of 0 or 1 Over Time up to Week 52 (Maintenance)
ParticipantsAIN457 Low DoseAIN457 High DosePlacebo-AIN457 Low DosePlacebo-AIN457 High DoseEtanercept
Week 2419178917
Week 3621219812
Week 52202281116
SecondaryNumber and Percentage of Participants With Clinically Important Reduction in Disability as Evaluated by CHAQ Questionnaire Over Time at Week 12

The CHAQ questionnaire is only done for children who in addition to psoriasis are also suffering from psoriatic arthritis. The questionnaire is completed by parent or legal guardian. It consists of multiple choice items concerning difficulty in performing eight common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and other "activities". The person completing the questionnaire chooses from four response categories, ranging from 'without any difficulty' to 'unable to do'. Additionally two visual analog scales (overall well-being and pain of patient) must be performed.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number and Percentage of Participants With Clinically Important Reduction in Disability as Evaluated by CHAQ Questionnaire Over Time at Week 12
ParticipantsAIN457 Low DoseAIN457 High DosePlaceboEtanercept
Number and Percentage of Participants With Clinically Important Reduction in Disability as Evaluated by CHAQ Questionnaire Over Time at Week 122002
SecondaryNumber and Percentage of Participants With Clinically Important Reduction in Disability as Evaluated by CHAQ Questionnaire Over Time at Week 52

The CHAQ questionnaire is only done for children who in addition to psoriasis are also suffering from psoriatic arthritis. The questionnaire is completed by parent or legal guardian. It consists of multiple choice items concerning difficulty in performing eight common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and other "activities". The person completing the questionnaire chooses from four response categories, ranging from 'without any difficulty' to 'unable to do'. Additionally two visual analog scales (overall well-being and pain of patient) must be performed.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number and Percentage of Participants With Clinically Important Reduction in Disability as Evaluated by CHAQ Questionnaire Over Time at Week 52
ParticipantsAIN457 Low DoseAIN457 High DosePlacebo- AIN457 Low DosePlacebo- AIN457 High DoseEtanercept
Number and Percentage of Participants With Clinically Important Reduction in Disability as Evaluated by CHAQ Questionnaire Over Time at Week 5220102

Adverse events

Collected over Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Any AIN457 Low Dose0/56 (0%)7/56 (12.5%)48/56 (85.7%)
Any AIN457 High Dose0/58 (0%)8/58 (13.8%)50/58 (86.2%)
Any AIN457 Dose0/114 (0%)15/114 (13.2%)98/114 (86%)
Placebo0/41 (0%)0/41 (0%)19/41 (46.3%)
Etanercept0/41 (0%)6/41 (14.6%)30/41 (73.2%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventAny AIN457 Low DoseAny AIN457 High DoseAny AIN457 DosePlaceboEtanercept
Abdominal painGastrointestinal disorders0/560/580/1140/411/41
Autoimmune pancreatitisGastrointestinal disorders0/560/580/1140/411/41
Gastrointestinal toxicityGastrointestinal disorders0/560/580/1140/411/41
Gallbladder polypHepatobiliary disorders0/560/580/1140/411/41
Pilonidal diseaseInfections and infestations0/560/580/1140/411/41
SyncopeNervous system disorders0/560/580/1140/411/41
Ectopic pregnancyPregnancy, puerperium and perinatal conditions0/560/580/1140/411/41
BronchitisInfections and infestations1/560/581/1140/410/41
CellulitisInfections and infestations1/560/581/1140/410/41
Alanine aminotransferase increasedInvestigations1/560/581/1140/410/41
Most frequent other events
Showing 10 of 49
Most frequent other events
EventAny AIN457 Low DoseAny AIN457 High DoseAny AIN457 DosePlaceboEtanercept
NasopharyngitisInfections and infestations17/5625/5842/1141/4111/41
TonsillitisInfections and infestations11/567/5818/1140/411/41
HeadacheNervous system disorders11/5611/5822/1144/414/41
PharyngitisInfections and infestations9/568/5817/1144/413/41
CoughRespiratory, thoracic and mediastinal disorders4/569/5813/1140/412/41
AcneSkin and subcutaneous tissue disorders8/565/5813/1141/410/41
DiarrhoeaGastrointestinal disorders7/567/5814/1140/411/41
Upper respiratory tract infectionInfections and infestations7/563/5810/1143/413/41
Glomerular filtration rate decreasedInvestigations7/564/5811/1140/411/41
PsoriasisSkin and subcutaneous tissue disorders7/561/588/1140/414/41

Baseline characteristics

The randomized set was defined as all patients who were randomized. Mis-randomized patients were excluded from the randomized set. If patients were re screened and successfully randomized, they were included in the randomized set according to the treatment assigned in the last randomization.

Age, Continuous
Age, Continuous(Years)AIN457 Low DoseAIN457 High DosePlaceboEtanerceptTotal
Mean13.7 ± 2.9213.2 ± 3.2113.7 ± 3.2713.5 ± 2.9413.5 ± 3.06
Age, Customized
Age, Customized(Participants)AIN457 Low DoseAIN457 High DosePlaceboEtanerceptTotal
<12 years89101037
>=12 years32313131125
Sex: Female, Male
Sex: Female, Male(Participants)AIN457 Low DoseAIN457 High DosePlaceboEtanerceptTotal
Female2723222597
Male1317191665
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AIN457 Low DoseAIN457 High DosePlaceboEtanerceptTotal
Caucasian34343630134
Black11002
Asian12137
Native American333817
Other10102
08

Study locations

46 sites
  • Novartis Investigative Site
    San Antonio, Texas 78218, United States
  • Novartis Investigative Site
    Bruxelles, 1200, Belgium
  • Novartis Investigative Site
    Gent, 9000, Belgium
  • Novartis Investigative Site
    Liege, 4000, Belgium
  • Novartis Investigative Site
    Medellin, Antioquia 05001000, Colombia
  • Novartis Investigative Site
    Bogota, 110221, Colombia
  • Novartis Investigative Site
    Alexandria, 21131, Egypt
  • Novartis Investigative Site
    Cairo, 11341, Egypt
  • Novartis Investigative Site
    Tartu, 51014, Estonia
  • Novartis Investigative Site
    Amiens Cedex 1, 80054, France
  • Novartis Investigative Site
    Nice, 06202, France
  • Novartis Investigative Site
    Paris 15, 75015, France
  • Novartis Investigative Site
    Bad Bentheim, 48455, Germany
  • Novartis Investigative Site
    Bochum, 44791, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Muenchen, 80377, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    Guatemala city, 01010, Guatemala
  • Novartis Investigative Site
    Guatemala City, 1015, Guatemala
  • Novartis Investigative Site
    Budapest, 1125, Hungary
  • Novartis Investigative Site
    Budapest, H-1089, Hungary
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
  • Novartis Investigative Site
    Afula, 1834111, Israel
  • Novartis Investigative Site
    Be'er Sheva, 8457108, Israel
  • Novartis Investigative Site
    Ramat Gan, 52621, Israel
  • Novartis Investigative Site
    Parma, PR 43100, Italy
  • Novartis Investigative Site
    Roma, RM 00133, Italy
  • Novartis Investigative Site
    Nagoya-city, Aichi 467-8602, Japan
  • Novartis Investigative Site
    Riga, LV-1001, Latvia
  • Novartis Investigative Site
    Riga, LV-1004, Latvia
  • Novartis Investigative Site
    Lodz, 90-265, Poland
  • Novartis Investigative Site
    Lublin, 20-079, Poland
  • Novartis Investigative Site
    Warszawa, 03-924, Poland
  • Novartis Investigative Site
    Cluj Napoca, Cluj 400006, Romania
  • Novartis Investigative Site
    Kazan, 420012, Russian Federation
  • Novartis Investigative Site
    Krasnodar, 350020, Russian Federation
  • Novartis Investigative Site
    Moscow, 119296, Russian Federation
  • Novartis Investigative Site
    Saint Petersburg, 191123, Russian Federation
  • Novartis Investigative Site
    Yekaterinburg, 620076, Russian Federation
  • Novartis Investigative Site
    Esplugues De Llobregat, Barcelona 08950, Spain
  • Novartis Investigative Site
    Barcelona, 08041, Spain
  • Novartis Investigative Site
    Madrid, 28046, Spain
  • Novartis Investigative Site
    Zuerich, CH - 8032, Switzerland
  • Novartis Investigative Site
    Scunthorpe, DN15 7GB, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Dec 2018, 38 months.

Results were first posted in Aug 2021, 2 years 8 months after primary completion. A results delay was requested in Aug 2019.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 38 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2015
First posted
Jun 15, 2015
StartActual
Sep 29, 2015
Primary completionActual
Dec 13, 2018
CompletionActual
Mar 30, 2023
Results delay requested
Aug 20, 2019
Results first posted
Aug 16, 2021
Last update
Oct 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02471144
Responsible party
Sponsor
First posted
Jun 15, 2015
Start date
Sep 29, 2015
Primary completion
Dec 13, 2018
Completion
Mar 30, 2023
Results posted
Aug 16, 2021
Last update
Oct 11, 2023

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion